Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The opioid growth factor (OGF) and its receptor, OGFr, serve as a tonically active inhibitory axis regulating the proliferation of human ovarian cancer cells. In the present study, we have investigated the repercussion on the progression of this deadly neoplasia when cells are engineered to molecularly under-express OGFr. shRNA constructs were used to knockdown OGFr in SKOV-3 cells; two clonal cell lines were examined. OGFr protein expression was decreased up to 73% in clones compared with wild-type (WT) and empty vector (EV) controls. OGFr-binding assays of clones revealed 50-55% decreases in binding capacity compared with control cells; binding affinity was comparable in all groups. Cell number in clones was increased 33-132%, and doubling times decreased 29-35%, compared with WT and EV cultures. Addition of exogenous OGF or naltrexone did not affect cell number in cultures with silenced OGFr. DNA synthesis of clonal cell lines was increased 136-146% from the WT and EV groups; no changes were noted in cell survival. Nude mice injected subcutaneously with cells under-expressing OGFr had an increased tumor incidence, decreased latency to tumor formation, increased tumor volume and decreased OGFr expression in tumors compared with WT and EV controls. OGF treatment in mice with WT or EV tumors, but not OGFr under-expressing tumors, inhibited tumor volume and weight. Collectively, these data demonstrate the critical nature of the OGF-OGFr axis as a determinant of the progression of human ovarian cancer, and suggest that attenuation of this system has an important bearing on the survival of these patients.

Original languageEnglish (US)
Pages (from-to)167-177
Number of pages11
JournalExperimental Biology and Medicine
Volume237
Issue number2
DOIs
StatePublished - Feb 1 2012

Fingerprint

Ovarian Neoplasms
Tumors
Tumor Burden
Opioid Analgesics
Cells
Neoplasms
Intercellular Signaling Peptides and Proteins
Clone Cells
Cell Count
Cell Line
Naltrexone
Nude Mice
Small Interfering RNA
methionine-enkephalin receptor
Cell culture
Cell Survival
Assays
Survival
DNA
Incidence

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

@article{ac67c86735964bbd9529edc4b9517684,
title = "Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer",
abstract = "The opioid growth factor (OGF) and its receptor, OGFr, serve as a tonically active inhibitory axis regulating the proliferation of human ovarian cancer cells. In the present study, we have investigated the repercussion on the progression of this deadly neoplasia when cells are engineered to molecularly under-express OGFr. shRNA constructs were used to knockdown OGFr in SKOV-3 cells; two clonal cell lines were examined. OGFr protein expression was decreased up to 73{\%} in clones compared with wild-type (WT) and empty vector (EV) controls. OGFr-binding assays of clones revealed 50-55{\%} decreases in binding capacity compared with control cells; binding affinity was comparable in all groups. Cell number in clones was increased 33-132{\%}, and doubling times decreased 29-35{\%}, compared with WT and EV cultures. Addition of exogenous OGF or naltrexone did not affect cell number in cultures with silenced OGFr. DNA synthesis of clonal cell lines was increased 136-146{\%} from the WT and EV groups; no changes were noted in cell survival. Nude mice injected subcutaneously with cells under-expressing OGFr had an increased tumor incidence, decreased latency to tumor formation, increased tumor volume and decreased OGFr expression in tumors compared with WT and EV controls. OGF treatment in mice with WT or EV tumors, but not OGFr under-expressing tumors, inhibited tumor volume and weight. Collectively, these data demonstrate the critical nature of the OGF-OGFr axis as a determinant of the progression of human ovarian cancer, and suggest that attenuation of this system has an important bearing on the survival of these patients.",
author = "Donahue, {Renee N.} and Mclaughlin, {Patricia J.} and Zagon, {Ian S.}",
year = "2012",
month = "2",
day = "1",
doi = "10.1258/ebm.2011.011321",
language = "English (US)",
volume = "237",
pages = "167--177",
journal = "Experimental Biology and Medicine",
issn = "1535-3702",
publisher = "SAGE Publications Ltd",
number = "2",

}

Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer. / Donahue, Renee N.; Mclaughlin, Patricia J.; Zagon, Ian S.

In: Experimental Biology and Medicine, Vol. 237, No. 2, 01.02.2012, p. 167-177.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer

AU - Donahue, Renee N.

AU - Mclaughlin, Patricia J.

AU - Zagon, Ian S.

PY - 2012/2/1

Y1 - 2012/2/1

N2 - The opioid growth factor (OGF) and its receptor, OGFr, serve as a tonically active inhibitory axis regulating the proliferation of human ovarian cancer cells. In the present study, we have investigated the repercussion on the progression of this deadly neoplasia when cells are engineered to molecularly under-express OGFr. shRNA constructs were used to knockdown OGFr in SKOV-3 cells; two clonal cell lines were examined. OGFr protein expression was decreased up to 73% in clones compared with wild-type (WT) and empty vector (EV) controls. OGFr-binding assays of clones revealed 50-55% decreases in binding capacity compared with control cells; binding affinity was comparable in all groups. Cell number in clones was increased 33-132%, and doubling times decreased 29-35%, compared with WT and EV cultures. Addition of exogenous OGF or naltrexone did not affect cell number in cultures with silenced OGFr. DNA synthesis of clonal cell lines was increased 136-146% from the WT and EV groups; no changes were noted in cell survival. Nude mice injected subcutaneously with cells under-expressing OGFr had an increased tumor incidence, decreased latency to tumor formation, increased tumor volume and decreased OGFr expression in tumors compared with WT and EV controls. OGF treatment in mice with WT or EV tumors, but not OGFr under-expressing tumors, inhibited tumor volume and weight. Collectively, these data demonstrate the critical nature of the OGF-OGFr axis as a determinant of the progression of human ovarian cancer, and suggest that attenuation of this system has an important bearing on the survival of these patients.

AB - The opioid growth factor (OGF) and its receptor, OGFr, serve as a tonically active inhibitory axis regulating the proliferation of human ovarian cancer cells. In the present study, we have investigated the repercussion on the progression of this deadly neoplasia when cells are engineered to molecularly under-express OGFr. shRNA constructs were used to knockdown OGFr in SKOV-3 cells; two clonal cell lines were examined. OGFr protein expression was decreased up to 73% in clones compared with wild-type (WT) and empty vector (EV) controls. OGFr-binding assays of clones revealed 50-55% decreases in binding capacity compared with control cells; binding affinity was comparable in all groups. Cell number in clones was increased 33-132%, and doubling times decreased 29-35%, compared with WT and EV cultures. Addition of exogenous OGF or naltrexone did not affect cell number in cultures with silenced OGFr. DNA synthesis of clonal cell lines was increased 136-146% from the WT and EV groups; no changes were noted in cell survival. Nude mice injected subcutaneously with cells under-expressing OGFr had an increased tumor incidence, decreased latency to tumor formation, increased tumor volume and decreased OGFr expression in tumors compared with WT and EV controls. OGF treatment in mice with WT or EV tumors, but not OGFr under-expressing tumors, inhibited tumor volume and weight. Collectively, these data demonstrate the critical nature of the OGF-OGFr axis as a determinant of the progression of human ovarian cancer, and suggest that attenuation of this system has an important bearing on the survival of these patients.

UR - http://www.scopus.com/inward/record.url?scp=84857277477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857277477&partnerID=8YFLogxK

U2 - 10.1258/ebm.2011.011321

DO - 10.1258/ebm.2011.011321

M3 - Article

C2 - 22328595

AN - SCOPUS:84857277477

VL - 237

SP - 167

EP - 177

JO - Experimental Biology and Medicine

JF - Experimental Biology and Medicine

SN - 1535-3702

IS - 2

ER -